2025年4月26日， 昊海生物发布了2024年年报。 # 财报数据 2024年公司实现营业 收入26.98亿元 ，同比 增长1.64% 。归属于母公司股东的净利润为4.20亿元，同比增 长1.04%。整体毛利率为69.88%，同比下降0.63个百分点。 费用变动 现金流 正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 昊海生物科技（股票代码：688366.SH / 06826.HK）成立于2007年1月24日，是一家专注于生物医用材料 研发、生产和销售的高科技生物医药企业。公司总部位于上海，注册资金1.2亿元人民币，主要从事生物材 料、生物制剂、基因工程药品的研发、生产和销售。 昊海生物科技的主营业务涵盖以下领域： 医疗美容与创面护理产品 公司是 国内第一 大手术防粘连剂生产商，2023年市场份额为28.82%，连续十七年稳居市场首位。 玻尿酸产品 ：公司是国内知名玻尿酸生产商之一，自主研发掌握了单相交联、低温二次交联、线性无颗 粒化交联以及有机交联等交联工艺。第一代产品"海薇"、第二代产品"姣兰"和第三代产品"海魅"已获得 市场广泛认可。 表皮修复基因工程制剂 ...

Financial Performance - The company reported total revenue of 619 million yuan for Q1 2025, a decrease of 4.25% year-on-year [1] - The net profit attributable to shareholders was 90.31 million yuan, down 7.41% compared to the same period last year [1] - The gross margin was 69.52%, an increase of 0.44% year-on-year, while the net profit margin decreased to 13.55%, down 5.36% [1] - Total expenses (selling, administrative, and financial) amounted to 272 million yuan, accounting for 43.96% of revenue, an increase of 5.94% year-on-year [1] - Earnings per share (EPS) was 0.39 yuan, a decrease of 7.14% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable represented 77.11% of the latest annual net profit, indicating a significant amount of outstanding payments [1] - Operating cash flow per share was 0.37 yuan, down 18.22% year-on-year [1] Business Model and Market Position - The company's return on invested capital (ROIC) was 5.01%, indicating average capital returns [3] - The net profit margin for the previous year was 13.95%, suggesting high added value for products or services [3] - The company relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3] Future Expectations - Analysts expect the company's performance in 2025 to reach 505 million yuan, with an average EPS forecast of 2.17 yuan [4] Fund Holdings - The largest fund holding the company’s shares is Tianhong Pension 2035 Three-Year (FOF) A, with 12,400 shares newly entered into the top ten holdings [5] - The fund's current scale is 120 million yuan, with a net value of 1.0282 as of April 23, showing a 0.12% increase from the previous trading day [5] Product Performance - The company anticipates a 65% year-on-year increase in hyaluronic acid product sales in 2024, despite a slowdown in growth due to market conditions [7]

Financial Performance - The company's operating revenue for 2024 reached RMB 2,697,657,908.35, representing a 1.64% increase compared to RMB 2,654,039,068.79 in 2023[22]. - The net profit attributable to shareholders for 2024 was RMB 420,446,906.16, a slight increase of 1.04% from RMB 416,121,340.71 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 379,096,331.64, showing a decrease of 1.12% compared to RMB 383,406,434.26 in 2023[22]. - The net cash flow from operating activities for 2024 was RMB 648,571,330.09, an increase of 2.23% from RMB 634,449,395.83 in 2023[22]. - As of the end of 2024, the net assets attributable to shareholders were RMB 5,575,258,634.87, a decrease of 1.32% from RMB 5,650,064,203.23 at the end of 2023[22]. - The total assets at the end of 2024 amounted to RMB 7,121,392,176.35, reflecting a slight increase of 0.22% from RMB 7,105,496,951.15 at the end of 2023[22]. - The company's gross profit margin for 2024 was 69.89%, slightly down from 70.46% in the previous year[32]. - The company achieved a revenue of 2,529.85 billion yuan in the pharmaceutical manufacturing industry in 2024, ranking 16th among 41 industrial categories, with a profit total of 342.07 billion yuan, a year-on-year decrease of 1.1%[80]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is CNY 6.00 per 10 shares, totaling CNY 138,023,048.40 (including tax) based on a total share capital of 233,193,695 shares, after deducting 3,155,281 shares held in the repurchase account[8]. - The total cash dividend for 2024, including interim distributions, amounts to CNY 230,925,296.80, representing 54.92% of the net profit attributable to shareholders of the listed company[8]. - The company plans to submit the profit distribution proposal to the 2024 annual general meeting of shareholders for approval[8]. Research and Development - Research and development expenses for 2024 amounted to CNY 238.93 million, an increase of CNY 18.83 million, or approximately 8.56% year-on-year, representing 8.86% of total revenue[33]. - The company has a dedicated R&D team of 350 members, accounting for 16.23% of total employees, including 25 PhD holders and 107 master's degree holders[161]. - The company is actively pursuing clinical trials for various new products, including pain-reducing cross-linked sodium hyaluronate gel, which is currently in clinical testing[104]. - The company has established a comprehensive R&D management system and innovation incentive mechanism to enhance its technological capabilities[165]. - The company has filed for 56 new patents during the reporting period, with 59 patents granted, bringing the total to 468[98]. Product Development and Innovation - The company launched the world's first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and received approval for its ophthalmic sodium hyaluronate eye drops in March 2024[33]. - The company is focusing on the integration of technologies such as stem cells, tissue engineering, and 3D printing to expand the application of biomedical materials in medical fields[86]. - The company is currently developing new products, including hydrophilic continuous vision intraocular lenses and collagen solutions for skin care, with R&D investments starting in 2024[178]. - The company is advancing various projects in the ophthalmology field, with multiple artificial lens products completing clinical trials and receiving regulatory certifications in early 2025[162]. - The company has developed a patented technology for medical chitosan, which has won multiple national awards, highlighting its innovation capabilities[107]. Market Position and Strategy - The company is committed to maintaining compliance with regulatory standards set by the National Medical Products Administration (NMPA)[16]. - Future outlook includes market expansion strategies and potential mergers and acquisitions to enhance competitive positioning[16]. - The company aims to leverage its research capabilities to drive innovation in medical devices and biopharmaceuticals[16]. - The company is focusing on four major therapeutic areas: medical aesthetics, ophthalmology, orthopedics, and adhesion prevention, which are expected to drive future growth[145]. - The company is actively engaged in the development of new products and technologies, focusing on the biomedical sector[192]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[7]. - The board of directors and supervisory board members confirm the authenticity, accuracy, and completeness of the annual report[4]. - The governance structure is designed to ensure clear responsibilities and effective decision-making processes within the company[197]. Risks and Challenges - The company faces risks related to technological advancements in the biomedical materials field, which could impact its market competitiveness if it fails to adapt[115]. - The company is exposed to operational risks, including potential product quality issues that could lead to recalls and reputational damage[116]. - The company is affected by industry risks due to ongoing reforms in the pharmaceutical and medical device sectors, which may increase compliance costs and reduce product demand[117]. - The company's growth is partially dependent on the overall growth of the biopharmaceutical industry in China, which could slow down due to various factors[118]. - The company has pursued international expansion through acquisitions, which may be impacted by changes in foreign regulations or geopolitical tensions[118].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司第 五屆監事會第二十一次會議決議公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年4月25日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告 ...

Financial Performance - The company's operating revenue for Q1 2025 was RMB 618,542,128.87, a decrease of 4.25% compared to RMB 645,995,271.22 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2025 was RMB 90,312,072.67, down 7.41% from RMB 97,541,532.98 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was RMB 88,474,729.61, reflecting a decrease of 7.08% compared to RMB 95,217,851.02 in the previous year[9]. - The total revenue for the first quarter of 2025 was CNY 618,542,128.87, a decrease of approximately 4.5% compared to CNY 645,995,271.22 in the first quarter of 2024[24]. - The operating profit for the first quarter of 2025 was CNY 103,806,860.81, compared to CNY 114,427,839.61 in the first quarter of 2024, indicating a decline of approximately 9.1%[24]. - Net profit for Q1 2025 was approximately ¥83.81 million, a decrease of 9.1% compared to ¥92.49 million in Q1 2024[25]. - Total comprehensive income for Q1 2025 reached approximately ¥106.29 million, an increase of 49.2% from ¥71.27 million in Q1 2024[25]. - Basic and diluted earnings per share for Q1 2025 were both RMB 0.39, down 7.14% from RMB 0.42 in the same period last year[9]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.39, down from ¥0.42 in Q1 2024[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 13.04% to RMB 85,876,398.75, compared to RMB 75,969,702.64 in the same period last year[9]. - Cash flow from operating activities for Q1 2025 was approximately ¥85.88 million, an increase of 13.5% compared to ¥75.97 million in Q1 2024[28]. - Cash flow from investing activities for Q1 2025 showed a net outflow of approximately ¥179.29 million, compared to a net inflow of ¥159.29 million in Q1 2024[28]. - Cash flow from financing activities for Q1 2025 resulted in a net outflow of approximately ¥79.08 million, compared to a net inflow of ¥42.14 million in Q1 2024[29]. - The cash and cash equivalents as of March 31, 2025, were CNY 2,544,062,908.38, a decrease from CNY 2,630,205,433.37 as of December 31, 2024[21]. - The cash and cash equivalents at the end of Q1 2025 were approximately ¥944.67 million, an increase from ¥846.19 million at the end of Q1 2024[29]. Research and Development - Research and development expenses totaled RMB 48,418,019.42, a decrease of 25.40% from RMB 64,900,123.30 year-on-year[9]. - R&D expenses accounted for 7.83% of operating revenue, down from 10.05% in the previous year, a reduction of 2.22 percentage points[9]. - The company reported a decrease in R&D expenses to CNY 48,418,019.42 in the first quarter of 2025, down from CNY 64,900,123.30 in the same period last year, reflecting a reduction of approximately 25.5%[24]. Assets and Equity - Total assets at the end of the reporting period were RMB 7,127,388,076.14, a slight increase of 0.08% from RMB 7,121,392,176.35 at the end of the previous year[9]. - Equity attributable to shareholders increased by 1.68% to RMB 5,669,029,445.16 from RMB 5,575,258,634.87 at the end of the previous year[9]. - The total liabilities as of March 31, 2025, were CNY 1,175,145,054.36, a decrease from CNY 1,204,351,783.01 as of December 31, 2024[22]. - The equity attributable to shareholders as of March 31, 2025, was CNY 5,669,029,445.16, an increase from CNY 5,575,258,634.87 at the end of 2024[22]. Inventory and Costs - The company's inventory as of March 31, 2025, was CNY 488,198,643.67, slightly down from CNY 490,650,955.52 at the end of 2024[21]. - The total operating costs for the first quarter of 2025 were CNY 510,997,863.52, down from CNY 535,026,579.06 in the same period last year, reflecting a reduction of about 4.5%[24]. - The company experienced a significant increase in other comprehensive income, with a net amount of approximately ¥22.48 million in Q1 2025, compared to a loss of ¥21.22 million in Q1 2024[25]. Capital Changes - The company completed a capital reserve conversion to increase share capital, issuing 66,782,692 new shares in 2024[9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 修訂《公司章程》 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.51(1)條而作出。 茲提述本公司於2024年5月29日召開之2023年度股東週年大會、2024年第一次A 股類別股東大會及2024年第一次H股類別股東大會審議通過的關於授予本公司董 事會（「董事會」）回購H股的一般性授權的議案（「2024年回購授權」）。根據2024年 回購授權，本公司於自2024年6月27日至本公告日的期間共計回購2,629,100股H 股，其中2,296,200股H股已完成註銷。 上述2,296,200 股H股註銷完成後，本公司股份總數由 235,489,895 股變更 為 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥618,542,128.87, a decrease of 4.25% compared to ¥645,995,271.22 in the same period last year[4] - The net profit attributable to shareholders was ¥90,312,072.67, down 7.41% from ¥97,541,532.98 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥88,474,729.61, reflecting a decrease of 7.08% compared to ¥95,217,851.02 in the previous year[4] - Total revenue for Q1 2025 was ¥618.54 million, a decrease of 4.9% compared to ¥645.99 million in Q1 2024[16] - Net profit for Q1 2025 was ¥83.81 million, a decline of 9.4% from ¥92.49 million in Q1 2024[16] - Basic earnings per share for Q1 2025 were ¥0.39, compared to ¥0.42 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 13.04% to ¥85,876,398.75, compared to ¥75,969,702.64 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥85,876,398.75, an increase of 13.5% compared to ¥75,969,702.64 in Q1 2024[19] - Total cash inflow from operating activities was ¥640,948,930.38, down 9.1% from ¥705,232,753.89 in the previous year[19] - The net cash flow from investing activities was -¥179,294,387.16, a significant decrease from ¥159,290,447.77 in Q1 2024[19] - The net cash flow from financing activities was -¥79,079,486.98, compared to a positive cash flow of ¥42,137,675.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,127,388,076.14, a slight increase of 0.08% from ¥7,121,392,176.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to ¥7.13 billion, slightly up from ¥7.12 billion at the end of 2024[14] - Total liabilities decreased to ¥1.18 billion as of March 31, 2025, from ¥1.20 billion at the end of 2024[14] - The company’s total equity increased to ¥5.95 billion as of March 31, 2025, from ¥5.92 billion at the end of 2024[14] Research and Development - Research and development expenses totaled ¥48,418,019.42, a decrease of 25.40% from ¥64,900,123.30 year-on-year[4] - Research and development expenses for Q1 2025 were ¥48.42 million, a decrease of 25.5% from ¥64.90 million in Q1 2024[16] - The proportion of R&D expenses to operating revenue was 7.83%, down from 10.05% in the previous year, a reduction of 2.22 percentage points[4] Inventory and Cash Equivalents - The company reported an increase in inventory to ¥488.20 million as of March 31, 2025, compared to ¥490.65 million at the end of 2024[13] - Cash and cash equivalents were ¥2.54 billion as of March 31, 2025, down from ¥2.63 billion at the end of 2024[13] - The total cash and cash equivalents at the end of Q1 2025 were ¥944,673,243.30, an increase from ¥846,192,318.84 in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains of ¥1,837,343.06 for the period, primarily from government subsidies and asset disposals[7]

環境，社會 與管治報告 2024 | 目錄 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 關於本報告 | 2 | 關於本公司 | 4 | | | | | | 年度主要榮譽及績效亮點 | 5 | | | | | | | | 管理 | ESG | | | | | | | | 治理架構 | ESG | 8 | | | | | | | 01 | | | | | | | | | 董事會聲明 | 8 | 利益相關方溝通 | 9 | | | | | | 雙重重要性評估 | 10 | | | | | | | | 合規運營 | | | | | | | | | 風險管理與內部控制 | 13 | | | | | | | | 02 | | | | | | | | | 商業道德 | 14 | 信息安全與隱私保護 | 16 | | | | | | 科技倫理 | 17 | | | | | | | | 產品與創新 | | | | | | | | | 研發創新 | 19 | 03 | 知識產權保護 | 24 | | | | | 供應鏈安全 | 25 | ...

Financial Performance - The company reported a revenue of RMB 2,679.67 million for 2024, an increase of RMB 44.76 million, representing a growth of 1.70% compared to the previous year[10]. - Net profit attributable to shareholders was approximately RMB 420.45 million, remaining stable compared to the previous year[10]. - Gross profit for 2024 was RMB 1,868.79 million, with a gross margin of 69.7%[9]. - The company’s net profit margin was 15.6%, slightly down from 15.7% in the previous year[9]. - The company’s basic earnings per share for 2024 was RMB 1.80, compared to RMB 1.75 in 2023[9]. - The overall revenue for the company in the reporting period was approximately RMB 2,679.67 million, an increase of RMB 44.76 million or 1.70% from RMB 2,634.91 million in 2023[59]. - The company's gross profit margin for the reporting period was 69.74%, a slight decrease of 0.60 percentage points from 70.34% in 2023[61]. - Other income and gains for the reporting period amounted to approximately RMB 149.76 million, an increase of about RMB 15.47 million or 11.52% compared to RMB 134.29 million in 2023, primarily due to the recognition of performance compensation from minority shareholders of a subsidiary[62]. Research and Development - Research and development expenses amounted to RMB 238.93 million, an increase of RMB 18.83 million, reflecting a growth of about 8.56% and accounting for 8.92% of total revenue[11]. - R&D expenses for the reporting period were approximately RMB 238.93 million, an increase of about RMB 18.83 million or 8.56% from RMB 220.10 million in 2023, reflecting the company's ongoing investment in expanding its ophthalmology and medical aesthetics product lines[63]. - The company is actively developing advanced artificial lens products, including hydrophobic and hydrophilic extended depth of focus lenses, with clinical trials expected to begin in July 2024[39]. - The company is advancing its research on hydrophilic aspheric multifocal intraocular lenses, with clinical trials completed and registration expected in early 2025[42]. Product Development and Market Expansion - The company successfully launched the globally first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and sodium hyaluronate eye drops were approved in March 2024[11]. - The company is expanding its product lines in aesthetic medicine and ophthalmology, with several key projects in clinical trials, including high oxygen permeability scleral lenses[11]. - The group’s hyaluronic acid product line achieved revenue of RMB 737.86 million in 2024, an increase of RMB 138.45 million, representing a growth rate of 23.10% compared to the previous year[28]. - The total revenue from medical beauty and wound care products reached RMB 1,189.22 million, up RMB 136.42 million, with a growth rate of approximately 12.96%[22]. - The company plans to expand the application of hEGF products into various medical fields, including pediatrics and oncology, beyond traditional uses[28]. - The company plans to focus on four rapidly developing treatment areas: medical beauty, wound care, ophthalmology, and orthopedics, emphasizing research and innovation[54]. Market Trends and Competitive Position - The market for non-surgical beauty treatments in China is expected to grow by about 10% in 2024, with a projected compound annual growth rate of 10-15% over the next four years[26]. - The Chinese medical beauty market size grew from RMB 99.3 billion in 2017 to RMB 189.2 billion in 2021, with a compound annual growth rate of 17.5%[24]. - The penetration rate of medical beauty treatments in China is significantly lower than in Brazil, the US, and South Korea, indicating potential for future market growth[24]. - The company achieved a market share increase in the orthopedic sector, rising from 46.54% in 2022 to 50.44% in 2023, solidifying its position as the leading manufacturer of viscoelastic supplements for joint injections in China[46]. Financial Management and Shareholder Returns - The company distributed a total of RMB 166,956,729.00 as final dividends and increased share capital by 66,782,692 shares by the end of July 2024[13]. - For the first half of 2024, the company distributed interim dividends totaling RMB 92,902,248.40[13]. - The board proposed a final dividend of RMB 0.6 per share (before tax) for the year ending December 31, 2024, totaling RMB 138,023,048.4 (before tax) based on the total issued shares of 233,193,695, after accounting for treasury shares[89]. - The company has adopted a dividend policy that emphasizes a balance between reasonable returns to investors and sustainable development[97]. - The company aims for a minimum cash dividend proportion of 80% for mature stages without significant capital expenditure[98]. Regulatory and Compliance - The company emphasizes the importance of environmental protection and has established and continuously improved its environmental management systems, ensuring compliance with pollution discharge standards[85]. - The company has not encountered any significant violations of environmental laws and regulations during the reporting period[85]. - The company has complied with all applicable provisions of the corporate governance code under the Hong Kong Listing Rules during the reporting period[186]. - There are no significant legal proceedings or arbitrations involving the company during the reporting period[187]. Employee and Management Structure - The company had approximately 2,156 employees as of December 31, 2024, with total employee compensation amounting to approximately RMB 692.94 million, an increase of about RMB 62.86 million from the previous year[70]. - The company’s employee compensation policy aims to enhance governance structure and motivate core teams to improve competitiveness[145]. - Non-executive directors receive fixed remuneration based on their background, experience, and responsibilities, with no additional director remuneration for executive directors[144]. Share Repurchase and Capital Management - The company repurchased 1,418,934 A-shares, accounting for 0.61% of total shares, with a total transaction amount of approximately RMB 106.27 million[13]. - A total of 2,492,100 H-shares were repurchased during the year, with a total expenditure of HKD 75,709,045.00[120]. - The board believes that the share repurchase enhances investor confidence and aligns the interests of shareholders, the company, and employees[121]. Governance and Stakeholder Engagement - The company maintains good relationships with stakeholders, including customers, shareholders, government agencies, employees, suppliers, and the community, to achieve medium- and long-term goals[86]. - The company has established a governance structure consisting of the general meeting of shareholders, the board of directors, the supervisory board, and the management team[195].

Shanghai Haohai Biological Technology Co., Ltd. 上海昊海生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號： 6826) 28 April 2025 Dear registered shareholder(s), Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 24 January 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Shanghai Haohai Biologi ...